TY - JOUR
T1 - An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer
AU - Berry, Emily
AU - Matthews, Kellie S.
AU - Singh, Diljeet K.
AU - Buttin, Barbara M.
AU - Lurain III, John Robert
AU - Alvarez, Ronald D.
AU - Schink, Julian
PY - 2009/4/1
Y1 - 2009/4/1
N2 - Objectives: To assess the feasibility, associated toxicities, and reasons for early cessation of an outpatient intraperitoneal (IP) chemotherapy regimen for treatment of advanced ovarian cancer following optimal cytoreductive surgery. Methods: Between January 2006 and December 2007, 42 patients with stages IIC-IV epithelial ovarian, tubal, or primary peritoneal cancer who had residual disease < 1 cm after cytoreductive surgery were treated with an outpatient IP chemotherapy protocol. Patients received intravenous (IV) docetaxel 75 mg/m2 and IP cisplatin 75-100 mg/m2 on day 1, followed by IP paclitaxel 60 mg/m2 on day 8, with the intent to treat patients every 21 days for 6 cycles of chemotherapy. Charts were abstracted for demographic, chemotherapy, and toxicity-related data. Results: The median age of the 42 patients was 59 years (range 33-70) and the majority of patients had epithelial ovarian cancer (80%), FIGO stage IIIC (83%), and papillary serous histology (74%). Of an intended 252 IP chemotherapy cycles, 172 (68%) were administered. Twenty-nine patients (69%) completed ≥ 4 cycles and 12 (29%) received all 6 IP cycles. Common grade 3/4 toxicities by patient included neutropenia (43%), infection (21.5%), and gastrointestinal effects (14%). There was one treatment-related death. Reasons for discontinuation were largely chemotherapy (43%) or port (37%) related. Conclusions: With supportive measures, such as scheduled hydration and granulocyte colony-stimulating factors, outpatient administration of IP chemotherapy was feasible. This regimen resulted in few hospitalizations or treatment delays and demonstrated less toxicity than previously reported IP chemotherapy regimens. Port-related complications were a leading cause of IP chemotherapy discontinuation.
AB - Objectives: To assess the feasibility, associated toxicities, and reasons for early cessation of an outpatient intraperitoneal (IP) chemotherapy regimen for treatment of advanced ovarian cancer following optimal cytoreductive surgery. Methods: Between January 2006 and December 2007, 42 patients with stages IIC-IV epithelial ovarian, tubal, or primary peritoneal cancer who had residual disease < 1 cm after cytoreductive surgery were treated with an outpatient IP chemotherapy protocol. Patients received intravenous (IV) docetaxel 75 mg/m2 and IP cisplatin 75-100 mg/m2 on day 1, followed by IP paclitaxel 60 mg/m2 on day 8, with the intent to treat patients every 21 days for 6 cycles of chemotherapy. Charts were abstracted for demographic, chemotherapy, and toxicity-related data. Results: The median age of the 42 patients was 59 years (range 33-70) and the majority of patients had epithelial ovarian cancer (80%), FIGO stage IIIC (83%), and papillary serous histology (74%). Of an intended 252 IP chemotherapy cycles, 172 (68%) were administered. Twenty-nine patients (69%) completed ≥ 4 cycles and 12 (29%) received all 6 IP cycles. Common grade 3/4 toxicities by patient included neutropenia (43%), infection (21.5%), and gastrointestinal effects (14%). There was one treatment-related death. Reasons for discontinuation were largely chemotherapy (43%) or port (37%) related. Conclusions: With supportive measures, such as scheduled hydration and granulocyte colony-stimulating factors, outpatient administration of IP chemotherapy was feasible. This regimen resulted in few hospitalizations or treatment delays and demonstrated less toxicity than previously reported IP chemotherapy regimens. Port-related complications were a leading cause of IP chemotherapy discontinuation.
KW - Antineoplastic combined chemotherapy
KW - Cisplatin
KW - Intraperitoneal chemotherapy
KW - Outpatient
KW - Ovarian adenocarcinoma
KW - Paclitaxel
UR - http://www.scopus.com/inward/record.url?scp=62549086510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62549086510&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2008.12.035
DO - 10.1016/j.ygyno.2008.12.035
M3 - Article
C2 - 19201457
AN - SCOPUS:62549086510
SN - 0090-8258
VL - 113
SP - 63
EP - 67
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -